Zymeworks(ZYME) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [27] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [28][29] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [30] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under collaboration agreements [27] - The company reported regulatory approvals for zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, which is expected to translate into regulatory milestone payments of up to $440 million [12][13] Market Data and Key Metrics Changes - Consensus estimates for peak sales of zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [12] - The company expects cumulative revenue contributions through royalties and milestones to scale meaningfully as use broadens across indications and geographies [14] Company Strategy and Development Direction - The company aims to leverage a validated scaling asset to secure efficient non-dilutive capital while preserving long-term upside [16] - Zymeworks plans to deploy capital dynamically across royalty asset acquisitions and share repurchase programs, maintaining flexibility based on market conditions [24] - The company intends to integrate new partnerships and collaborations into its existing wholly owned portfolio to share funding and risk [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA [7] - The company anticipates continued discipline in capital allocation and expects adjusted gross operating expenses in 2026 to be approximately 20% lower than in 2025 [32] - Management highlighted the importance of maintaining a robust R&D operation while integrating partnerships and collaborations to enhance funding [89] Other Important Information - The company announced a strategic financing agreement with Royalty Pharma, providing $250 million of low-cost non-dilutive capital [16] - The company retains 70% of the royalty stream throughout the duration of the royalty-backed note, preserving cash flows for reinvestment [18] Q&A Session Summary Question: Regarding GPC3 ADC ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in the ZW191 program [45][48] Question: Timing of royalty-backed financing and acquisition opportunities - Management clarified that the timing for the royalty note completion was influenced by the commercialization cycle of zanidatamab and the current cost of capital [54][56] Question: Expectations for AACR and internal R&D updates - Management hinted at significant updates on both multispecifics and ADC capabilities at the upcoming AACR conference [58][60] Question: Recent data on pasritamig and its emerging profile - Management expressed enthusiasm regarding pasritamig's safety and efficacy profile, noting positive feedback from physicians [69] Question: Types of assets targeted for acquisitions and cash runway considerations - Management stated that no acquisitions are included in the cash runway forecast, emphasizing a disciplined approach to capital deployment [74][76]